PatientsVille.com Logo

MUSCLE SPASMS and Mirtazapine

PatientsVille

MUSCLE SPASMS Symptoms and Causes

Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.

Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow.

There are three types of angina:

  • Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help.
  • Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon.
  • Variant angina is rare. It happens when you are resting. Medicines can help.

Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for MUSCLE SPASMS

MUSCLE SPASMS treatment research studies

Mirtazapine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Mirtazapine Side Effects

Completed Suicide (237)
Confusional State (206)
Hyponatraemia (180)
Depression (160)
Overdose (148)
Anxiety (147)
Fall (136)
Dizziness (130)
Agitation (130)
Condition Aggravated (123)
Somnolence (117)
Insomnia (113)
Headache (110)
Serotonin Syndrome (109)
Suicidal Ideation (107)
Fatigue (105)
Loss Of Consciousness (104)
Convulsion (103)
Aggression (103)
Suicide Attempt (100)
Nausea (96)
Oedema Peripheral (93)
Dyspnoea (92)
Weight Increased (90)
Tachycardia (90)
Tremor (84)
Malaise (82)
Vomiting (75)
Restless Legs Syndrome (75)
Myalgia (73)
Alanine Aminotransferase Increased (72)
Cardiac Arrest (71)
Inappropriate Antidiuretic Hormone Secretion (71)
Feeling Abnormal (70)
Toxicity To Various Agents (69)
Asthenia (69)
Diarrhoea (67)
Syncope (62)
Hyperhidrosis (61)
Neuroleptic Malignant Syndrome (61)
Pain In Extremity (61)
Electrocardiogram Qt Prolonged (60)
Pyrexia (59)
Aspartate Aminotransferase Increased (58)
Pulmonary Embolism (57)
Arthralgia (56)
Hypotension (56)
Irritability (56)
Pain (55)
Gait Disturbance (54)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i have been on citalopram and amatripolineand fluxaitne i have been on 15mg of mirtazapine and tryed 30mg the doc has put me on 45mg and i asked if these tablets dont work what is next hes said shrink as i have tryed all the ones he said but i have

My symptoms were tired, weak, unable to sleep. Was prescribed half of a 15 MG Mirtazapine nightly to help me sleep. Has this drug been successful used as a sleeping aid?

The above comment is too stupid, I actually LOLed at you Pete... lol you gave it 2 days and your complaining about the side-effects? and on 15 mgs? LMAO!!! It takes couple weeks at least to cope with the side-effects; just like m

48 year old male, I have suffered depression all my life. Have used SSRI's for the last ten years with good but mixed results. Last year lost my job due to an episode where I ended up throwing my monitor across the office and have not been able to wo

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

Back pain

Been on 90mg mirtazapine for 6 years twice the recomended dose is this considered safe

Body covered in hives

Calf twitches

Calfs constly twitching

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

muscle cramping when in a dead sleep

I just had the infusion two days ago (1/19/10) and was surprised with the intensity of muscle pain the day after the treatment. My pain was localized to my rib cage, neck, shoulders and upper back. In addition I was very fatiqued...slept most of

I started taking this medicine geodon 40 mg once a day. Then i notice i was blinking a lot. Then i started having eye muscle spasms several times a day.Now i have to go to the eye dr.I stop taking the medicine. Til I see what the dr.says.

I was having frequent leg cramps. They worked their way from my foot up to my thigh. I just thought it was from stopping the use of muscle relaxers ( for a serious back and neck problem). I had forgotten about them and never mentioned it to either

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

one 10 mg pill cuased presure in thechest bad muslespasms in the back think past doses has sent me skizzo

<b>Describe Your Pravastatin Experience Here:</b> I have been on 20 mg since Jan. And have been having muscle pain in the back of the thighs? Has anyone felt muscle pain in that area. Don't know if it is from medication or exercise

I received an injection close to my shoulder blade June 16, 2010. Three months later, I have an indentation and my health care provider has indicated that perhaps the muscle has scare tissue and the indentation and disc

<span style='color: #808080;'><b>I experienced severe neck spasms the day after receiving my second shot of Gardasil. It's been 2 days with no releif. The doctor did not inform me of the side effects in fact she said '

MUSCLE SPASMS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Evaluation of Mirtazapine and Folic Acid for Schizophrenia:
Conditions: Schizophrenia;   Negative Symptoms
Interventions: Drug: Mirtazapine and folic acid;   Drug: Mirtazapine, folic acid placebo;   Drug: Mirtazapine placebo, folic acid;   Drug: Mirtazapine placebo, folic acid placebo
Outcome Measures: To compare the efficacy of Mirtazapine and placebo for treatment of symptoms associated with schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of symptoms of schizophrenia;   To compare the efficacy of Mirtazapine and placebo for treatment of negative symptoms of schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of negative symptoms of schizophrenia;   To compare the safety and tolerability of Mirtazapine and placebo in patients with schizophrenia;   To compare the safety and tolerability of folic acid and placebo in patients with schizophrenia
2 Recruiting Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement
Condition: Major Depression
Interventions: Drug: Mirtazapine, paroxetine;   Drug: Mirtazapine;   Drug: paroxetine 20mg QD
Outcome Measures: Change of 17-item Hamilton Depression Scale (HAMD-17) total score;   The proportion of subjects at endpoint with HAMD-17≤7;   The incidence and nature of overall adverse events;   The incidence and nature of drug-related adverse events;   The number of subject withdrawal due to adverse events during double-blind phase
3 Recruiting Pharmacogenetic Study of Mirtazapine Response in Depressed Patients
Condition: Depression
Intervention: Drug: Mirtazapine
Outcome Measures: Mirtazapine response at 2,4,6 weeks and adverse events (A/E) monitoring at 1,2,4,6 weeks;   Biological value at 0 and 6 weeks
4 Unknown  Mirtazapine Versus Placebo in Functional Dyspepsia
Condition: Functional Dyspepsia
Intervention: Drug: Mirtazapine
Outcome Measures: Difference in dyspepsia symptom scores week 8 versus week 0;   Individual symptom severities;   Nepean dyspepsia index for quality of life in functional dyspepsia
5 Recruiting Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Mirtazapine plus gemcitabine;   Drug: Gemcitabine, placebo
Outcome Measures: quality of life;   anxiety and depression scores;   objective response rate;   progress free survival,;   overall Survival;   chemotherapy induced nausea and vomiting
6 Recruiting Mirtazapine for Sleep Disorders in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Sleep Disorders
Intervention: Drug: Mirtazapine
Outcome Measures: Change From Baseline in Nighttime Total Sleep Time;   Change From Baseline in Nighttime Number Of Awakenings;   Change From Baseline in Nighttime Wake After Sleep Onset;   Change From Baseline in in Daytime Total Sleep Time;   Change From Baseline in Number of Daytime Naps;   Change in Cognitive Function (as Measured by the Mini-Mental State Examination);   Change in Activities of Daily Living (The Index of ADL - Katz);   Change of Baseline in Behavioral Variables (BAHAVE-AD Scale);   Change From Baseline in Cognitive Function (Digit Symbol Substitution Test)
7 Recruiting LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
Condition: Major Depressive Disorder
Intervention: Drug: Mirtazapine
Outcome Measures: increase in weight as measured in the clinic;   Proportion of population achieving clinical response as measured by rate of fall in HAM-D 24 item scores;   Proportion of patients achieving remission at end of study on HAM-D 24 (<11);   Frequency of adverse events;   Percentage adhering to medication
8 Recruiting Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
Condition: Depression
Interventions: Drug: Mirtazapine;   Other: Supportive psychotherapy
Outcome Measures: Change from baseline in Hamilton Depression Rating Scale (HAMD)-17 at 8 weeks;   Change from baseline in quality of life at 8 weeks;   Genetic polymorphism
9 Recruiting Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
Condition: Methamphetamine
Interventions: Drug: Mirtazapine;   Drug: Placebo
Outcome Measures: Number of methamphetamine-positive urine tests;   Sexual risk (see description)
10 Recruiting Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Condition: Autism Spectrum Disorders
Interventions: Drug: Placebo;   Drug: Mirtazapine
Outcome Measures: Pediatric Anxiety Rating Scale (PARS);   Clinical Global Impressions (CGI)
11 Unknown  Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
Condition: Depressive Disorder, Major
Interventions: Drug: Mirtazapine;   Drug: Venlafaxine
Outcome Measures: Categorial response to the medication. Categorial response is defined on the basis of CGI Improvement scale and 50% reduction in MADR-S score;   Tolerability of treatment as assessed using the DOTES scale;   Cognitive deficits as judged by the SKT system;   Self assessment of depression and anxiety using Beck's Depression/Anxiety Inventory (BDI/BAI);   Changes is blood levels of homocysteine, folate, vit B12, P11
12 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
13 Unknown  Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients
Condition: Depression
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: depressive symptoms;   Distress level
14 Recruiting Strategic Use of New Generation Antidepressants for Depression
Condition: Unipolar Major Depressive Episode
Interventions: Drug: Sertraline;   Drug: Mirtazapine
Outcome Measures: Observer-rated depression severity (PHQ-9);   Self-rated depression severity (BDI-II);   Global rating of side effects (FIBSER)
15 Recruiting Predict Antidepressant Responsiveness Using Pharmacogenomics
Conditions: Depression;   Depressive Symptoms
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measure: Presences of each individual symptom of depression at 1,2,4,6,12 weeks
16 Recruiting Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
Conditions: Depression;   Adverse Reaction to Drug
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks;   Biological value at 0 and 6 weeks
17 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
18 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
19 Recruiting Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Condition: Lumbar Spinal Stenosis
Interventions: Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;   Procedure: Lumbar epidural injection;   Other: Joint Mobilizations (spine, sacroiliac, hip);   Other: Individualized exercises: clinical setting;   Other: Group Exercise: community setting
Outcome Measures: Swiss Spinal Stenosis Questionnaire Score;   Self Paced Walking Test
20 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)